Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
Jennifer R. Brown(Dana-Farber Cancer Institute), Mazyar Shadman(University of Washington), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Tommi Salmi(Düsseldorf University Hospital), Andrzej Mital(Gdańsk Medical University), Habte Yimer(Texas Oncology), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Peter Ganly(European Bioinformatics Institute), Constantine S. Tam(The Alfred Hospital), Megan Wang, Anders Österborg(Karolinska University Hospital), Keshu Zhou(Zhengzhou University), Jiřı́ Mayer(Masaryk University), Amanda Gillespie-Twardy(Düsseldorf University Hospital), Sebastian Grosicki(Medical University of Silesia), Kenneth Wu(Düsseldorf University Hospital), Martin Šimkovič(Charles University), Tadeusz Robak(Medical University of Lodz), Barbara Eichhorst(University of Cologne), Liping Wang(Chinese Academy of Sciences), Jessica Li(Universidad San Carlos), Maciej Kaźmierczak(Silesian University of Technology), Wojciech Jurczak(Jagiellonian University), Aileen Cleary Cohen, Robert Weinkove(Malaghan Institute of Medical Research), Luqui Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College), Susan O’Brien(University of California, Irvine)
Cited by 24
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k